Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda Gray, James G. Kublin, Matsontso Mathebula et al.|The Lancet Infectious Diseases|2011Cited by 385
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Scott Parker, Marnie Elizaga et al.|The Journal of Infectious Diseases|2013Cited by 197
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsPaul Goepfert, Helen Horton, M. Juliana McElrath et al.|The Journal of Infectious Diseases|2005Cited by 65